333 related articles for article (PubMed ID: 33140457)
1. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
Changou CA; Shiah HS; Chen LT; Liu S; Luh F; Liu SH; Cheng YC; Yen Y
Oncologist; 2021 Mar; 26(3):e367-e373. PubMed ID: 33140457
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
Yen Y; So S; Rose M; Saif MW; Chu E; Liu SH; Foo A; Jiang Z; Su T; Cheng YC
Anticancer Res; 2009 Oct; 29(10):4083-92. PubMed ID: 19846955
[TBL] [Abstract][Full Text] [Related]
3. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.
Saif MW; Li J; Lamb L; Kaley K; Elligers K; Jiang Z; Bussom S; Liu SH; Cheng YC
Cancer Chemother Pharmacol; 2014 Feb; 73(2):373-80. PubMed ID: 24297682
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Hsu CH; Yang TS; Hsu C; Toh HC; Epstein RJ; Hsiao LT; Chen PJ; Lin ZZ; Chao TY; Cheng AL
Br J Cancer; 2010 Mar; 102(6):981-6. PubMed ID: 20160718
[TBL] [Abstract][Full Text] [Related]
7. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
He SL; Shen J; Sun XJ; Zhu XJ; Liu LM; Dong JC
World J Gastroenterol; 2013 Jul; 19(28):4552-8. PubMed ID: 23901232
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.
Yau T; Cheng PNM; Chiu J; Kwok GGW; Leung R; Liu AM; Cheung TT; Ng CT
Invest New Drugs; 2022 Apr; 40(2):314-321. PubMed ID: 34735674
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Poh SB; Bai LY; Chen PM
Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
[TBL] [Abstract][Full Text] [Related]
11. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
[TBL] [Abstract][Full Text] [Related]
12. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
Front Immunol; 2022; 13():944062. PubMed ID: 36091003
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Abdel-Rahman O; Abdel-Wahab M; Shaker M; Abdel-Wahab S; Elbassiony M; Ellithy M
Med Oncol; 2013; 30(3):655. PubMed ID: 23824645
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
16. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Brandi G; de Rosa F; Agostini V; di Girolamo S; Andreone P; Bolondi L; Serra C; Sama C; Golfieri R; Gramenzi A; Cucchetti A; Pinna AD; Trevisani F; Biasco G;
Oncologist; 2013; 18(12):1256-7. PubMed ID: 24232581
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka AO
Invest New Drugs; 2014 Aug; 32(4):762-8. PubMed ID: 24737402
[TBL] [Abstract][Full Text] [Related]
18. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma.
Brandi G; Di Federico A; Rizzo A; De Lorenzo S; Vasuri F; Brocchi S; Golfieri R; Morelli MC; Frega G; Palloni A
Anticancer Drugs; 2022 Jan; 33(1):e781-e783. PubMed ID: 34407053
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine for treatment of advanced hepatocellular carcinoma.
von Delius S; Lersch C; Mayr M; Stock K; Schulte-Frohlinde E; Schmid RM; Eckel F
Hepatogastroenterology; 2007 Dec; 54(80):2310-4. PubMed ID: 18265654
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
